ScreenerHero

HEPAHepion Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · hepionpharma.com
0.0750USD+22.95%Mkt Cap: 6.77M $P/E: —

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It develop…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.77M $
Enterprise Value6.83M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.28M $
Revenue/Share—
Last Price0.0750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4268971045
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-5.36
EPS (TTM)-0.03
EPS (Forward)-11.43
52W Range
0.034054% of range0.1100
52W High0.1100 USD
52W Low0.0340 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-310.32%
ROA-269.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.27M $
CapEx (TTM)—
FCF Margin—
FCF Yield-6.03%
Net Debt-1.63M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio3.91
Quick Ratio3.31
Book Value/Sh-0.0140 USD
Cash/Share0.0180 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 3, 2019
Splits
Last Split1:50
Split DateMar 18, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.90.22M
Float71.15M
Insiders30.20%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Float4.10%
Short % Out.4.10%
Shares Short448.18K
Short (prev mo.)199.81K
Technical
SMA 500.0611 (+22.7%)
SMA 2000.0598 (+25.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)22.34K
Avg Vol (10d)27.03K
Technical Indicators
RSI (14)60.3
MACD0.0034
MACD Signal0.0005
MACD Hist.+0.0029
BB Upper0.0743 USD
BB Middle0.0541 USD
BB Lower0.0338 USD
BB Width74.95%
ATR (14)0.0130 USD
Vol Ratio (20d)0.42x